A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixed-phenotype acute leukemia

Key Points

• The central aim is to assess the effectiveness of a lower-intensity protocol with venetoclax in treating mixed-phenotype acute leukemia in adults.
• Designed a treatment protocol involving venetoclax for newly diagnosed patients.
• Included adult participants diagnosed with mixed-phenotype acute leukemia.
• Evaluated the effectiveness based on clinical outcomes.
• The lower-intensity protocol showed promising clinical effectiveness.
• Patients exhibited positive response rates to treatment.
• Reduction in adverse effects compared to more intensive treatments.

Abstract